Recently, the Guangzhou Sino-Israel Bio-Industry Incubation Center (BIG) formally signed a strategic partnership agreement with DLRC—a renowned European team specializing in regulatory affairs and market access. Under this collaboration, the two parties will jointly provide comprehensive consulting services to both Chinese and international innovation teams, covering business development, clinical trials, technical validation, and legal compliance. This partnership is specifically designed to accelerate cross-border market entry for innovative projects and foster the coordinated growth of the global life science ecosystem.

DLRC is an award-winning consultancy team of >80 highly qualified, experienced regulatory professionals operating in UK, Germany, and US. With a deep commitment to excellence, DLRC is dedicated to helping clients navigate the complex regulatory landscape of the life science industry. DLRC develop and execute innovative phase-appropriate regulatory strategies, providing comprehensive support from early development to post-licensing activities for medicinal products and medical devices. The DLRC team comprises consultant experts in nonclinical, CMC, clinical and MedTech from pharmaceutical, medical device and regulatory agency backgrounds. They have proudly served companies of all sizes and backgrounds in various regulatory jurisdictions.

Since its establishment, BIG has leveraged government and industry resources accumulated through its in-depth collaboration with the Guangzhou International Bio-Island and Guangzhou Development District. This has enabled BIG to assist dozens of overseas startup teams in addressing key challenges such as policy access and regulatory compliance when entering the Chinese market, thereby facilitating the scientific validation of cutting-edge foreign innovative technologies and their subsequent application expansion within the local Guangzhou market.

Looking ahead, the partnership between BIG and DLRC will further support more European and American life science innovation teams in smoothly accessing the Chinese market. Simultaneously, it will equip Chinese enterprises with critical regulatory insights and strategies needed to succeed in their overseas expansion efforts. Together, the two partners will deliver two-way, end-to-end services focused on accelerating regulatory approval, clinical advancement, and commercialization for life science enterprises operating across borders.